Compare SYBT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYBT | MESO |
|---|---|---|
| Founded | 1904 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2009 | N/A |
| Metric | SYBT | MESO |
|---|---|---|
| Price | $72.39 | $15.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $76.00 | N/A |
| AVG Volume (30 Days) | 137.9K | ★ 199.5K |
| Earning Date | 04-22-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $23,406,000.00 | N/A |
| Revenue This Year | $17.31 | $629.74 |
| Revenue Next Year | $9.32 | $30.65 |
| P/E Ratio | $14.95 | ★ N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $61.51 | $9.88 |
| 52 Week High | $83.83 | $21.50 |
| Indicator | SYBT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 60.93 | 52.51 |
| Support Level | $72.29 | $15.62 |
| Resistance Level | $73.79 | $16.37 |
| Average True Range (ATR) | 1.82 | 0.39 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 64.64 | 51.72 |
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.